Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.68 USD | -8.07% | -13.54% | +51.86% |
05-15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
05-13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.86% | 1.32B | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-3.46% | 21.58B | |
-11.28% | 18.96B | |
-40.50% | 16.96B | |
-13.41% | 16.33B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-12-2022 10